Morepen Laboratories Limited
Morepen Laboratories Ltd is engaged in the business of manufacturing, producing, developing and marketing a wide range of Active Pharmaceutical Ingredients (APIs), branded and generic formulations and also the Home Health products.
What Morepen files
- Others58
- Important37
- Updates32
- Investor Meet9
- Board Meeting8
- PPTs6
Morepen Laboratories posted its highest-ever quarterly revenue of Rs. 575.31 Cr, up 34% YoY, signaling strong operational execution. Profit After Tax (PAT) surged 394% YoY to Rs. 56.35 Cr, with EBITDA growing 207% YoY to Rs. 87.72 Cr and margins hitting over 15%. This impressive performance reflects commercial validation of...
Here's a concise, retail-friendly summary of Morepen Laboratories' investor presentation: Morepen Laboratories saw Q4 FY26 revenue jump 22% YoY to Rs 472 Cr, driven by 17% API growth and a strong 31% surge in Medical Devices. Full FY26 revenue rose 8% to Rs 1703 Cr. The company is strategically shifting...
**Business Performance:** Morepen Labs recorded a strong Q3 FY26 with standalone gross revenue climbing 13% year-over-year (YoY) to ₹462 Cr. This growth was predominantly driven by the Medical Devices segment, which saw a significant 44% YoY increase, reaching ₹177 Cr. In contrast, the Pharma business remained flat YoY at ₹285...
Morepen Laboratories Limited has informed the Exchange about Investor Presentation
1. Financial Highlights: Consolidated revenue rose 7.4% to Rs. 1,830 Cr, with Q4 revenue up 10% to Rs. 470 Cr. EBITDA margin improved to 10.1%, supporting a 6.5% increase in PAT to Rs. 118 Cr. EPS gained 17% to Rs. 2.20. Pharma contributed 73% of revenues at Rs. 1,334 Cr...